Riverstonebio – – Revolutionizing Small Molecule Pharma with Synthetic Biology

Revolutionizing

SMALL MOLECULE PHARMA

WITH SYNTHETIC BIOLOGY

READ MORE
Focusing on

THE NOVEL PRODUCTION OF

SPECIFIC SMALL MOLECULE APIS

READ MORE

RIVER STONE USES SYNTHETIC BIOLOGY TO ENABLE NEW PHARMACEUTICAL APPROACHES

Synthetic Biology is disrupting multiple industries.

River Stone is a synthetic biology company with a focus on the novel production of specific small molecule APIs.

Significant advances in the ability to design, build and test biological and biochemical systems over the last two decades has enabled the creation of optimized manufacturing methodology that River Stone has applied to targeted molecules. Associated molecular assemblies and materials are cheaper, processes faster and processes more scalable than ever before.

Extensive experience in developing, scaling

WE HAVE A FULL

CAPABILITIES

Our team has taken multiple products

from idea to commercial launch

and commercializing specialty molecules

production methodology, manufacturing

SUITE OF SYNTHETIC

PIONEERING SYNTHETIC BIOLOGY

River Stone was founded in 2016 with a focus on API production route re-engineering. Our team has a track record in building pioneering synthetic biology and life science ventures. The team has brought multiple synbio and pharma products to market.

ENABLING SIMPLER ROUTES FOR THE

FRIENDLY PRODUCTION

Several of our pipeline API projects have

and have entered scale-up phase.

COMBINING SYNTHETIC BIOLOGY

reached commercially viable production levels

MANUFACTURING OF SPECIALTY APIS

& CHEMISTRY TO ALLOW FOR COST

TEAMS

Our teams have taken multiple products from idea to commercial launch.

Paul Goldenheim

CEO

Paul is trained as a pulmonary physician and is currently working as a director and consultant in the field of biotechnology, serving on the boards of directors of several companies including Adenium, and Hydra Biosciences. Paul has a long history in pharmaceutical research, development, and management, most recently as President of TransForm Pharmaceuticals (acquired by Johnson & Johnson) and Vice-Chairman of the Board of Directors of Hypnion (acquired by Eli Lilly). Paul also serves on the board of directors of Celebrity Series of Boston. Dr. Goldenheim received his AB from Harvard College magna cum laude with highest honors in biochemical sciences and his MD from Harvard Medical School.

Mr Richard (“Dick”) Cashin

President of One Equity Partners (“OEP”), a private equity firm that currently manages $7 billion for over 100 individual and institutional investors. In 1980, he joined Citigroup Venture Capital (President 1994-2000) and in 2001, founded OEP which became the private equity business of JP Morgan Chase before it was spun out in early 2015 to become an independent investment advisor. Dick holds a number of independent directorships and trustee positions and is active in a variety of philanthropic projects Dick has a BA in East Asian Studies from Harvard College (1975), an MBA from Harvard Business School (1980), was a member of the 1976 and 1980 U.S. Olympic Rowing Teams and was a world champion in 1974.

James (“Jeb”) Besser

Managing member and General Partner of Manchester Management LLC, a family of investment funds that invests in public and private equities, primarily in the health care space. He has been a managing member at Manchester since 1999. Prior to Manchester, Jeb worked at Highfields Capital and Media Group Investors in a variety of investment orientated roles. Jeb graduated from Brown University in 1997 with a B.A. in History, where he was a varsity rower and team captain

SENIOR TEAM

Extensive experience in developing, scaling production methodology, manufacturing and commercializing specialty molecules

Jørgen Hansen

CSO, CEO Denmark

From 2013-2018, Jørgen served as Evolva’s Chief Scientific Officer, running a five-site R&D organization with the full complement of synthetic biology, from idea stage and bioinformatics over strain development to scale-up of upstream and downstream processes. Before that and since 2005, he has directed the activities of the Evolva Copenhagen laboratory. Previously he worked at Poalis Biotech, a biotech startup from University of Copenhagen, Carlsberg Laboratory, the Danish Technical University and Aarhus University.

Simon Ball

COO

Prior to his appointment Simon was the Global Head of Business Development of the Leadiant Biosciences Group (formerly Sigma Tau Group) where he also served as Country General Manager in United Kingdom, Ireland and the Nordics between May 2014 – April 2018. Earlier, from October 2011 and April 2014, Simon held a number of senior positions within GlaxoSmithKline (GSK) across Asia Pacific. Simon has also held several senior positions in the areas of Business Development, Corporate Development and Emerging Markets with Cephalon Inc. (and formerly Zeneus Pharma Ltd), EUSA Pharma Ltd. (now Jazz Pharmaceuticals Inc.) and Takeda Pharmaceutical Company Limited. Simon obtained his degree in physiology from the University of Leeds, UK. At present Simon holds a board position with Exelead Inc. a privately held US domiciled CDMO.

Esben Halkjær Hansen

VP, R&D

Esben has 14 years of experience within microbial production strain development, pathway discovery, and optimization. From 2011-2017, Esben served as Program Manager at Evolva, running several different strain development programs and has successfully brought projects from idea phase, over strain optimization to production. Previously he has worked at Poalis Biotech. He has a PhD in Molecular Biology/Pharmaceutical Science from University of Copenhagen.

Tim Bowser

CDO

30+ years in GSK & Sun Pharma – R&D, BD, GM & API roles Developed products from lab to market. Co-author 3 Science papers on API biosynthesis.

Paul Goldenheim

CEO

Paula Hicks, SVP Technology & IP

SVP Technology & IP

Paula has 20 years of technology expertise in diverse industries utilizing biotechnology. From 2011 to 2018 Paula held several senior technical leadership roles at Evolva, Inc. successfully scaling up multiple projects and managing programs with industrial, university, and government partners. Prior to that she served as a technical program manager for biopharmaceutical projects at Bend Research, Inc. (now Lonza). Hicks started her career at Cargill leading development of new processes for food ingredients. She holds a Ph.D. in Chemical Engineering from North Carolina State University.

CONTACT AND INFORMATION

For questions regarding commercial partnerships and investors and collaboration with academic partners, please contact us. Feel free to call on us anytime.

RIVER STONE USES SYNTHETIC BIOLOGY TO ENABLE NEW PHARMACEUTICAL APPROACHES

READ MORE

PIONEERING SYNTHETIC BIOLOGY

River Stone was founded in 2016 with a focus on API production route re-engineering. Our team has a track record in building pioneering synthetic biology and life science ventures. The team has brought multiple synbio and pharma products to market.

READ MORE

TEAMS

SENIOR TEAM

CONTACT AND INFORMATION

For questions regarding commercial partnerships and investors and collaboration with academic partners, please contact us. Feel free to call on us anytime.

CONTACT INFO HERE

River Stone Biotech INC.

River Stone Biotech ApS

River Stone Biotech PTY LTD

CONTACT